Status:
COMPLETED
A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Low Back Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To compare the analgesic effectiveness of celecoxib and tramadol in subjects with Chronic Low Back Pain measured by the Numerical Rating Scale (NRS-Pain) at Week 6
Eligibility Criteria
Inclusion
- The subject presents with duration of chronic low back pain of \> 3 months requiring regular use of analgesics (\> 4 days/week), except for acetaminophen which cannot have been the sole analgesic used
Exclusion
- The subject has chronic low back pain, which is neurologic in etiology (i.e., radiculopathy, neuropathy, myelopathy)
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
802 Patients enrolled
Trial Details
Trial ID
NCT00662558
Start Date
January 1 2008
End Date
September 1 2008
Last Update
February 21 2021
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35126
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35235
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35242
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85023